165 related articles for article (PubMed ID: 36478911)
1. Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with
Tolmachev V; Bodenko V; Orlova A; Schulga A; Deyev SM; Vorobyeva A
Oncol Lett; 2023 Jan; 25(1):12. PubMed ID: 36478911
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
Vorobyeva A; Konovalova E; Xu T; Schulga A; Altai M; Garousi J; Rinne SS; Orlova A; Tolmachev V; Deyev S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392820
[TBL] [Abstract][Full Text] [Related]
4. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.
Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of [
Liu T; Wu Y; Shi L; Li L; Hu B; Wang Y; Gao H; Yu X; Zhang X; Zhao H; Wan Y; Jia B; Wang F
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1810-1821. PubMed ID: 35013776
[TBL] [Abstract][Full Text] [Related]
8. Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.
Deyev SM; Xu T; Liu Y; Schulga A; Konovalova E; Garousi J; Rinne SS; Larkina M; Ding H; Gräslund T; Orlova A; Tolmachev V; Vorobyeva A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298801
[TBL] [Abstract][Full Text] [Related]
9. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
10. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.
Xu T; Vorobyeva A; Schulga A; Konovalova E; Vorontsova O; Ding H; Gräslund T; Tashireva LA; Orlova A; Tolmachev V; Deyev SM
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439094
[TBL] [Abstract][Full Text] [Related]
11. EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer.
van den Brand D; van Lith SAM; de Jong JM; Gorris MAJ; Palacio-Castañeda V; Couwenbergh ST; Goldman MRG; Ebisch I; Massuger LF; Leenders WPJ; Brock R; Verdurmen WPR
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630661
[TBL] [Abstract][Full Text] [Related]
12. DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker.
Babaee N; Talebkhan Garoosi Y; Karimipoor M; Davami F; Bayat E; Safarpour H; Mahboudi F; Barkhordari F
Mol Biol Rep; 2020 Oct; 47(10):7323-7331. PubMed ID: 32979162
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3.
Oroujeni M; Bezverkhniaia EA; Xu T; Liu Y; Plotnikov EV; Klint S; Ryer E; Karlberg I; Orlova A; Frejd FY; Tolmachev V
Nucl Med Biol; 2023; 124-125():108384. PubMed ID: 37699299
[TBL] [Abstract][Full Text] [Related]
14. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
[TBL] [Abstract][Full Text] [Related]
15. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
Orlova A; Hofström C; Strand J; Varasteh Z; Sandstrom M; Andersson K; Tolmachev V; Gräslund T
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):439-49. PubMed ID: 23179942
[TBL] [Abstract][Full Text] [Related]
16. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
17. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer.
Houvast RD; Badr N; March T; de Muynck LDAN; Sier VQ; Schomann T; Bhairosingh S; Baart VM; Peeters JAHM; van Westen GJP; Plückthun A; Burggraaf J; Kuppen PJK; Vahrmeijer AL; Sier CFM
Eur J Nucl Med Mol Imaging; 2023 Aug; ():. PubMed ID: 37642704
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
20. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
